Gossamer Bio (GOSS)
(Delayed Data from NSDQ)
$1.05 USD
+0.06 (6.45%)
Updated Oct 1, 2024 04:00 PM ET
3-Hold of 5 3
D Value A Growth D Momentum B VGM
Income Statements
Fiscal Year end for Gossamer Bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 184 | 219 | 216 | 234 | 186 |
Income After Depreciation & Amortization | -184 | -219 | -216 | -234 | -186 |
Non-Operating Income | 17 | 3 | 2 | 3 | 6 |
Interest Expense | 14 | 14 | 19 | 13 | 0 |
Pretax Income | -180 | -229 | -234 | -243 | -180 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -180 | -229 | -234 | -243 | -180 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -180 | -229 | -234 | -243 | -180 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -188 | -214 | -204 | -226 | -185 |
Depreciation & Amortization (Cash Flow) | -4 | 4 | 12 | 8 | 1 |
Income After Depreciation & Amortization | -184 | -219 | -216 | -234 | -186 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 152.62 | 84.58 | 74.84 | 68.51 | 54.74 |
Diluted EPS Before Non-Recurring Items | -1.18 | -2.71 | -3.13 | -3.55 | -3.29 |
Diluted Net EPS (GAAP) | -1.18 | -2.71 | -3.13 | -3.55 | -3.29 |
Fiscal Year end for Gossamer Bio, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 95.84 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 95.84 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 43.76 | 41.96 | 49.03 | 40.49 | 46.30 |
Income After SG&A, R&D, and Dept/Amort Expenses | 52.08 | -41.96 | -49.03 | -40.49 | -46.30 |
Non-Operating Income | 4.50 | 3.16 | 4.12 | 3.83 | 7.23 |
Interest Expense | 2.92 | 3.13 | 3.24 | 3.34 | 3.43 |
Pretax Income | 53.67 | -41.93 | -48.15 | -40.01 | -42.50 |
Income Taxes | 4.44 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 49.23 | -41.93 | -48.15 | -40.01 | -42.50 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 49.23 | -41.93 | -48.15 | -40.01 | -42.50 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 226.22 | 225.74 | 225.41 | 192.88 | 95.45 |
Diluted EPS Before Non-Recurring Items | 0.22 | -0.19 | -0.21 | -0.21 | -0.45 |
Diluted Net EPS (GAAP) | 0.22 | -0.19 | -0.21 | -0.21 | -0.45 |